MedTrace Logo

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

NCT04496518 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2200

Last updated 2025-10-20

No results posted yet for this study

Summary

Medtronic is sponsoring the Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) to further confirm safety and effectiveness of ventricular iATP therapy in routine clinical practice, following commercial release of iATP-capable devices.

The iATP PAS is conducted within Medtronic's Product Surveillance Registry platform (NCT01524276).

Conditions

  • Ventricular Tachycardia

Interventions

DEVICE

Intrinsic Antitachycardia Pacing (iATP) Therapy

iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2024-11-06
Completion
2028-01-31
FDA Device
Yes

Countries

  • United States
  • France
  • Greece
  • Italy
  • Portugal
  • Slovakia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04496518 on ClinicalTrials.gov